Chardan Capital analyst Geulah Livshits reiterated a Buy rating on Rocket Pharmaceuticals (NASDAQ:RCKT) on Tuesday, setting a price target of $56, which is approximately 29.18% above the present share price of $43.35.
Livshits expects Rocket Pharmaceuticals to post earnings per share (EPS) of -$1.09 for the second quarter of 2021.
The current consensus among 9 TipRanks analysts is for a Strong Buy rating of shares in Rocket Pharmaceuticals, with an average price target of $69.86.
The analysts price targets range from a high of $80 to a low of $56.
In its latest earnings report, released on 12/31/2020, the company reported a quarterly revenue of $0 and a net profit of -$59.24 million. The company's market cap is $2.73 billion.
According to TipRanks.com, Chardan Capital analyst Geulah Livshits is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 60.9% and a 58.82% success rate.
Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of first-in-class gene therapy treatment options for rare and devastating pediatric diseases. Its multi-platform development approach applies the lentiviral vector (LVV) and adeno-associated viral vector (AAV) gene therapy platforms. The firm's clinical program is a LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. The company was founded in 1999 and is headquartered in New York, NY.